Odapipam
Odapipam is a selective D1 receptor antagonist of the benzazepine group which was investigated as a potential antipsychotic but was never marketed.
It has more than 5,000-fold selectivity for the dopamine D1 receptor over the dopamine D2 receptor. Its affinities for other dopamine receptors, such as the dopamine D5 receptor, were not reported. In addition to the dopamine D1 receptor, odapipam showed relatively high affinity for the serotonin 5-HT2 receptor.
The drug was first described in the scientific literature by 1988.